VICP — Vicapsys Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $57.30m
- $57.79m
- 15
- 58
- 58
- 40
Annual income statement for Vicapsys Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.03 | 0.766 | 0.337 | 0.985 | 1.05 |
| Operating Profit | -1.03 | -0.766 | -0.337 | -0.985 | -1.05 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.03 | -0.766 | -0.237 | -0.985 | -1.18 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.03 | -0.766 | -0.237 | -0.985 | -1.18 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -1.41 | -0.766 | -0.237 | -0.985 | -1.18 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.57 | -0.766 | -0.237 | -0.988 | -1.18 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.105 | -0.044 | -0.013 | -0.021 | -0.034 |